Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synexus has concluded patient enrollment in the Phase II study of CT327 in patients who are suffering from psoriasis, for the European biotech, Creabilis.
Subscribe to our email newsletter
Synexus has delivered the targeted number of patients within the agreed timelines.
Synexus chief executive Christophe Berthoux said the Synexus model works particularly well with companies like Creabilis who need to get their early phase studies underway fast.
"Each of our 26 Dedicated Research Centres has access to patient pools and use of our patient database with in excess of 450,000 pre-registered patients, to help recruit the right subjects rapidly," Berthoux said.